Patents Assigned to Incyte Corporation
  • Thiazolecarboxamides and pyridinecarboxamide compounds useful as PIM kinase inhibitors
    Patent number: 10517858
    Abstract: The present disclosure describes thiazole and pyridine carboxamide derivatives, their compositions and methods of use. The compounds inhibit the activity of the Pim kinases and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer and other diseases.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: December 31, 2019
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Chu-Biao Xue, Yun-Long Li, Hao Feng, Ke Zhang
  • Pyrrolopyrimidine derivatives as TAM inhibitors
    Patent number: 10519163
    Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: December 31, 2019
    Assignee: Incyte Corporation
    Inventors: Yun-Long Li, David M. Burns, Hao Feng, Joseph Glenn, Chunhong He, Song Mei, Jun Pan, Xiaozhao Wang, Yingda Ye
  • Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
    Patent number: 10513522
    Abstract: The present invention provides azetidinyl phenyl, pyridyl, or pyrazinyl carboxamide derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAKs) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: December 24, 2019
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Wenqing Yao, David M. Burns, Jincong Zhuo
  • Cyclopropylamines as LSD1 inhibitors
    Patent number: 10513493
    Abstract: The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: December 24, 2019
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Chunhong He, Ding-Quan Qian, Bo Shen, Wenqing Yao
  • Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
    Patent number: 10479803
    Abstract: This application relates to derivatives of Formula I: and pharmaceutically acceptable salts thereof, which are inhibitors of PI3K, and compositions and methods of treatment related thereto.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: November 19, 2019
    Assignee: Incyte Corporation
    Inventors: Yun-Long Li, Andrew P. Combs
  • Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines and substituted imidazo[1,2-b]pyridazines as PI3K-gamma inhibitors
    Patent number: 10479795
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: November 19, 2019
    Assignee: Incyte Corporation
    Inventors: Andrew W. Buesking, Richard B. Sparks, Andrew P. Combs, Brent Douty, Nikoo Falahatpisheh, Lixin Shao, Stacey Shepard, Eddy W. Yue, Artem Shvartsbart, David M. Burns, Daniel Levy
  • 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins
    Patent number: 10472358
    Abstract: The present invention relates to substituted pyrrolopyridinones and substituted pyrazolopyridinones which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: November 12, 2019
    Assignee: Incyte Corporation
    Inventors: Andrew P. Combs, Thomas P. Maduskuie, Jr., Nikoo Falahatpisheh
  • Heterocyclic compounds as PI3K-? inhibitors
    Patent number: 10472368
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: November 12, 2019
    Assignee: Incyte Corporation
    Inventors: Artem Shvartsbart, Stacey Shepard, Andrew P. Combs, Lixin Shao, Nikoo Falahatpisheh, Ge Zou, Andrew W. Buesking, Richard B. Sparks, Eddy W. Yue, Ravi Kumar Jalluri
  • Tricyclic heterocycles as BET protein inhibitors
    Patent number: 10464947
    Abstract: The present invention relates to tricyclic heterocycles of Formula (I): which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: November 5, 2019
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Andrew P. Combs, Richard B. Sparks, Thomas P. Maduskuie, Jr., James D. Rodgers
  • Bicyclic heterocycles as FGFR inhibitors
    Patent number: 10450313
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: October 22, 2019
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Liang Lu, Wenqing Yao, Chunhong He, Fenglei Zhang
  • Heterocyclic compounds useful as Pim kinase inhibitors
    Patent number: 10450296
    Abstract: The present application is concerned with heterocyclic compounds that inhibit the activity of Pim kinases and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancers and other diseases.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: October 22, 2019
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Yun-Long Li, Alexander Sokolsky, Anlai Wang, Wenyu Zhu, Jincong Zhuo
  • Processes of preparing a JAK1 inhibitor and new forms thereto
    Patent number: 10450325
    Abstract: This invention relates to processes for preparing a JAK1 inhibitor having Formula Ia: as well as new forms of the inhibitor.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: October 22, 2019
    Assignee: Incyte Corporation
    Inventors: Jiacheng Zhou, Zhongjiang Jia
  • Pyrrolotriazine compounds as TAM inhibitors
    Patent number: 10442810
    Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: October 15, 2019
    Assignee: Incyte Corporation
    Inventors: Yun-Long Li, Xiaozhao Wang, Chunhong He
  • Tricyclic heterocycles as bet protein inhibitors
    Patent number: 10442803
    Abstract: The present invention relates to tricyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: October 15, 2019
    Assignee: Incyte Corporation
    Inventors: James D. Rodgers, Stacey Shepard, Haisheng Wang, Lixin Shao
  • Pyrazolopyridine compounds and uses thereof
    Patent number: 10435405
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: October 8, 2019
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Kai Liu, Alexander Sokolsky, Anlai Wang, Hai Fen Ye, Qinda Ye, Wenqing Yao
  • Bipyrazole derivatives as JAK inhibitors
    Patent number: 10435392
    Abstract: The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: October 8, 2019
    Assignee: Incyte Corporation
    Inventors: Yun-Long Li, Jincong Zhuo, Ding-Quan Qian, Song Mei
  • Pyrimidinones as PI3K inhibitors
    Patent number: 10428087
    Abstract: The present invention provides pyrimidinones that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: October 1, 2019
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yun-Long Li, Brian W. Metcalf, Andrew P. Combs
  • Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
    Patent number: 10398699
    Abstract: The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: September 3, 2019
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: James D. Rodgers, Stacey Shepard
  • Heterocyclylamines as PI3K inhibitors
    Patent number: 10376513
    Abstract: The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: August 13, 2019
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Richard B. Sparks, Andrew P. Combs, Brent Douty, Yun-Long Li, Song Mei, Eddy W. Yue
  • 1,2,5-Oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
    Patent number: 10369137
    Abstract: The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: August 6, 2019
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Andrew P. Combs, Eddy W. Yue, Richard B. Sparks, Wenyu Zhu